List view / Grid view

Boehringer Ingelheim

news

Type 2 Diabetes: CHMP recommends empagliflozin for approval

21 March 2014 | By Boehringer Ingelheim

Positive opinion for investigational SGLT2 inhibitor empagliflozin for the treatment of T2D in adults...

news

Type 2 Diabetes: New poll of more than 700 Latin American physicians provides insights into complexity and challenges

14 March 2014 | By Boehringer Ingelheim

More than 73 percent of physicians surveyed said the complexity of Type 2 Diabetes is underestimated...

news

10,000 patients with atrial fibrillation now enrolled in innovative GLORIA™-AF Registry

11 March 2014 | By Boehringer Ingelheim

Boehringer Ingelheim announces the enrolment of the 10,000th patient with atrial fibrillation (AF) into GLORIA™-AF, one of the largest AF registry programmes currently running worldwide...

news

Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation

6 March 2014 | By Boehringer Ingelheim

More than 100 countries have now approved Boehringer Ingelheim’s Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition...

news

New Phase III data show tiotropium* Respimat® effective across asthma severities

3 March 2014 | By Boehringer Ingelheim

Boehringer Ingelheim announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities...

news

Boehringer Ingelheim receives East Bay Innovation Award

17 February 2014 | By Boehringer Ingelheim

Boehringer Ingelheim Fremont Inc. received the East Bay Innovation Award in recognition for its contribution to the East Bay's culture of innovation...

news

Crystal Bioscience and Boehringer Ingelheim announce multiple target antibody discovery collaboration

7 January 2014 | By Boehringer Ingelheim

Under the terms of the agreement, Crystal will receive an upfront technology access fee and research funding for each program...

news

Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant

16 December 2013 | By Boehringer Ingelheim,

"These data are encouraging as they demonstrate that HCV genotype-1 infected patients irrespective of the presence of the common HCV Q80K variant..."

news

New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism

10 December 2013 | By Boehringer Ingelheim

The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics...

news

New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes

3 December 2013 | By Boehringer Ingelheim

Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D).

news

Largest global survey investigating early type 2 diabetes conversations launched by Boehringer Ingelheim and Eli Lilly and Company in partnership with the International Diabetes Federation

2 December 2013 | By Boehringer Ingelheim

The survey was developed in partnership with the International Diabetes Federation (IDF) and will include more than 10,000 people with T2D and more than 6,500 treating-physicians...

news

Hepatitis C: Boehringer Ingelheim’s faldaprevir granted accelerated assessment from European Medicines Agency

26 November 2013 | By Boehringer Ingelheim

The application for European marketing authorisation of faldaprevir* has been fully validated and granted accelerated assessment by the European Medicines Agency...

news

New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years

19 November 2013 | By Boehringer Ingelheim

Pradaxa® is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role for stroke prevention...

news

Boehringer Ingelheim goes “Blue” in supporting World Diabetes Day activities

15 November 2013 | By Boehringer Ingelheim

"Run for Diabetes" raises €15,000 towards supporting "Life for a Child Programme..."

news

Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over

13 November 2013 | By Boehringer Ingelheim

"Our extensive studies have demonstrated that tiotropium Respimat® has the potential to be an effective new treatment..."

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Boehringer Ingelheim